Emtora Biosciences
1 known investors
Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).
Investors · 1
Competitors · 2
by search overlap
Mammoth Biosciences11 shared keywordsMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Emtora Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Emtora Biosciences do?
- Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).
- Who are Emtora Biosciences's investors?
- Emtora Biosciences's investors include UT Horizon Fund.